CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 74 enrolled
Drug / intervention
MP-424 +4 moredrug
Likely dose
MP-424 750mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01753570
NCT01753570Phase 3Completed
CompareCT.gov

A Phase 3 Study of MP-424 in Combination With IFN Beta and RBV, in Subjects With Genotype 1/2 Hepatitis C, Who Are Treatment-Naïve or Have Received Interferon Based Therapy

Tanabe Pharma Corporation·interventional·Posted Dec 20, 2012·Updated Jan 6, 2026

In Brief

A Phase 3 clinical trial evaluating MP-424, RBV(24 weeks), and 3 other interventions for Chronic Hepatitis C(CHC). Completed, enrolled 74 participants across 1 site.

Detailed Summary

This study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients with genotype 1/2 hepatitis C, who are treatment-naïve or have received its treatment before.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C(CHC)
CountriesJapan
CollaboratorsToray Industries, Inc

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 20, 2012
Enrollment StartDec 1, 2012
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.5 years ago

Interventions

MP-424drug

MP-424: 750mg every 8 hours (q8h) for 12 weeks

RBV(24 weeks)drug

RBV: 600 - 1000mg/day based on body weight for 24 weeks

IFN beta(24 weeks)drug

IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 24 weeks

RBV(48 weeks)drug

RBV: 600 - 1000mg/day based on body weight for 48 weeks

IFN beta(48 weeks)drug

IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 48 weeks